Long-term safety and efficacy of adalimumab for intestinal Behçet's disease in the open label study following a phase 3 clinical trial

Nagamu Inoue, Kiyonori Kobayashi, Makoto Naganuma, Fumihito Hirai, Morio Ozawa, Dilek Arikan, Bidan Huang, Anne M Robinson, Roopal B Thakkar, Toshifumi Hibi, Nagamu Inoue, Kiyonori Kobayashi, Makoto Naganuma, Fumihito Hirai, Morio Ozawa, Dilek Arikan, Bidan Huang, Anne M Robinson, Roopal B Thakkar, Toshifumi Hibi

Abstract

Background/aims: Intestinal Behçet's disease (BD) is an immune-mediated inflammatory disorder. We followed up the patients and evaluated safety profile and effectiveness of adalimumab for the treatment of intestinal BD through 100 weeks rolled over from the 52 week clinical trial (NCT01243671).

Methods: Patients initiated adalimumab therapy at 160 mg at week 0, followed by 80 mg at week 2, followed by 40 mg every other week until the end of the study. Long-term safety and all adverse events (AEs) were examined. The efficacy was assessed on the basis of marked improvement (MI) and complete remission (CR) using a composite efficacy index, which combined global gastrointestinal symptoms and endoscopic assessments.

Results: Twenty patients were enrolled in this study; 15 patients received adalimumab treatment until study completion. The incidence of AEs through week 100 was 544.4 events/100 person-years, which was comparable to the incidence through week 52 (560.4 events/100 person-years). No unexpected trend was observed and adalimumab was well tolerated. At weeks 52 and 100, 60.0% and 40.0% of patients showed MI, respectively, and 20.0% and 15.0% of patients showed CR, respectively.

Conclusions: This report demonstrates 2 years safety and effectiveness of adalimumab in intestinal BD patients. Patients with intestinal BD refractory to conventional treatment receiving up to 2 years of adalimumab treatment demonstrated safety outcomes consistent with the known profile of adalimumab, and the treatment led to sustained reduction of clinical and endoscopic disease activity.

Keywords: Behçet's disease, intestinal; Biological products; Endoscopy; Ulcer.

Conflict of interest statement

Conflict of interest: F.H. has received personal fees for lectures from AbbVie GK and his institution has received funding from AbbVie GK. D.A., B.H., A.M.R., and R.B.T. are employees of AbbVie Inc., and M.O. is an employee of AbbVie GK, and they may hold AbbVie stock or options. T.H. has received personal fees from Ajinomoto Pharmaceuticals Co. Ltd., Asahi Kasei Medical Co., Ltd., AstraZeneca Pharmaceuticals, Janssen Pharmaceutical K.K., JIMRO Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, UCB Japan Co., Ltd., UMN Pharma Inc., and Zeria Pharmaceutical Co., Ltd. The remaining authors disclose no conflicts of interest.

Figures

Fig. 1. Study design.
Fig. 1. Study design.
Fig. 2. Long-term efficacy as assessed by…
Fig. 2. Long-term efficacy as assessed by the composite efficacy index (A), global gastrointestinal symptom assessment (B), and endoscopic assessment (C).

References

    1. Sakane T, Takeno M, Suzuki N, Inaba G. Behçet's disease. N Engl J Med. 1999;341:1284–1291.
    1. Tanida S, Inoue N, Kobayashi K, et al. Adalimumab for the treatment of Japanese patients with intestinal Behçet's disease. Clin Gastroenterol Hepatol. 2015;13:940–948.e3.
    1. The diagnostic criteria for Behçet's disease (2003) Ministry of Health, Labour and Welfare Web site. [Accessed April 4, 2017]. .
    1. Hibi T, Hirohata S, Kikuchi H, et al. Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study. Medicine (Baltimore) 2016;95:e3863. doi: 10.1097/MD.0000000000003863.
    1. Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda AP. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis. 2013;72:517–524.
    1. Watanabe M, Hibi T, Mostafa NM, et al. Long-term safety and efficacy of adalimumab in Japanese patients with moderate to severe Crohn's disease. J Crohns Colitis. 2014;8:1407–1416.
    1. Panaccione R, Colombel JF, Sandborn WJ, et al. Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE. Aliment Pharmacol Ther. 2013;38:1236–1247.
    1. Hatemi G, Silman A, Bang D, et al. EULAR recommendations for the management of Behçet disease. Ann Rheum Dis. 2008;67:1656–1662.
    1. Hisamatsu T, Ueno F, Matsumoto T, et al. The 2nd edition of consensus statements for the diagnosis and management of intestinal Behçet’s disease: indication of anti-TNFalpha monoclonal antibodies. J Gastroenterol. 2014;49:156–162.
    1. Chung MJ, Cheon JH, Kim SU, et al. Response rates to medical treatments and long-term clinical outcomes of nonsurgical patients with intestinal Behçet disease. J Clin Gastroenterol. 2010;44:e116–e122. doi: 10.1097/MCG.0b013e3181c8a50f.
    1. Naganuma M, Iwao Y, Inoue N, et al. Analysis of clinical course and long-term prognosis of surgical and nonsurgical patients with intestinal Behçet's disease. Am J Gastroenterol. 2000;95:2848–2851.
    1. REMICADE: package insert. Osaka: Mitsubishi Tanabe Pharma Corporation; 2017.
    1. Lee JH, Cheon JH, Jeon SW, et al. Efficacy of infliximab in intestinal Behçet's disease: a Korean multicenter retrospective study. Inflamm Bowel Dis. 2013;19:1833–1838.
    1. Kinoshita H, Kunisaki R, Yamamoto H, et al. Efficacy of infliximab in patients with intestinal Behçet's disease refractory to conventional medication. Intern Med. 2013;52:1855–1862.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren